Patents by Inventor Michael A. Brennan
Michael A. Brennan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10978189Abstract: A computing entity accesses instances of medical information corresponding to a population of patients and generates a plurality of medical sentences corresponding to the population by, for each patient of the population, generating one medical sentence corresponding to the patient and a timestamp associated with each instance such that the one medical sentence comprises one or more medical codes in a chronological order. The computing entity generates a vector dictionary comprising a plurality of multi-dimensional vectors based on a vector generation model trained using machine learning and the plurality of medical sentences with each multi-dimensional vector corresponding to a medical code. The computing entity generates a digital representation of a first patient of the population using an anagram model and the vector dictionary, determines a health state of the first patient based on the digital representation, and provides an output indicating the health state of the first patient.Type: GrantFiled: November 30, 2018Date of Patent: April 13, 2021Assignee: Optum, Inc.Inventors: Patrick White, Somadev Pasala, Donald Johnson, Sreedhar Potturi, Dhaval Shah, Anthony Degliomini, Michael Brennan
-
Publication number: 20210009585Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.Type: ApplicationFiled: September 21, 2020Publication date: January 14, 2021Applicant: CELGENE QUANTICEL RESEARCH, INC.Inventors: Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Publication number: 20210009520Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.Type: ApplicationFiled: September 18, 2020Publication date: January 14, 2021Applicant: CELGENE QUANTICEL RESEARCH, INC.Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Patent number: 10870634Abstract: The present embodiments provide for substituted triazolylpyridine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for modulating the activity of histone demethylase enzymes. Additionally, the subject compounds and compositions are useful for the treatment of cancer or other neoplastic diseases, or maladies associated with abnormal histone demethylase activity. Accordingly, the substituted triazolylpyridine derivative compounds described herein are useful in methods and medicaments for treating cancer.Type: GrantFiled: March 16, 2020Date of Patent: December 22, 2020Assignee: CELGENE QUANTICEL RESEARCH, INC.Inventors: Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Patent number: 10815234Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.Type: GrantFiled: February 14, 2020Date of Patent: October 27, 2020Assignee: CELGENE QUANTICEL RESEARCH, INC.Inventors: Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Patent number: 10807956Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.Type: GrantFiled: February 5, 2020Date of Patent: October 20, 2020Assignee: CELGENE QUANTICEL RESEARCH, INC.Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Patent number: 10760531Abstract: A rocket throat insert including an annular body having a radially inner annular wall portion and a radially outer annular portion. The inner wall portion has a contoured radially inner surface defining a nozzle throat. The outer portion includes an annular buttressing structure supporting the inner wall portion and defining one or more insulation gaps arranged annularly around the inner wall portion. The insulation gaps restrict the radial flow of heat through the annular body.Type: GrantFiled: December 13, 2017Date of Patent: September 1, 2020Assignee: Raytheon CompanyInventors: Michael Brennan, Gray Fowler
-
Patent number: 10709234Abstract: An expandable table comprises first and second table surfaces connected by a first hinge at their adjoining short sides. First and second legs are fixed to an underside of the first table surface to support the first table surface. A third leg is fixed to an end of a slidable bar or mechanism wherein the slidable bar or mechanism is installed on an underside of the first table surface, wherein the slidable bar or mechanism is configured to be slid out from under the first table surface wherein the third leg provides support for the second table surface when the second table surface is unfolded and wherein the slidable bar or mechanism is configured to be slid under the first table surface wherein the third leg rests adjacent to the first leg when the second table surface is folded to lie on top of the first table surface.Type: GrantFiled: November 8, 2019Date of Patent: July 14, 2020Inventor: Michael Brennan
-
Publication number: 20200216420Abstract: The present embodiments provide for substituted triazolylpyridine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for modulating the activity of histone demethylase enzymes. Additionally, the subject compounds and compositions are useful for the treatment of cancer or other neoplastic diseases, or maladies associated with abnormal histone demethylase activity. Accordingly, the substituted triazolylpyridine derivative compounds described herein are useful in methods and medicaments for treating cancer.Type: ApplicationFiled: March 16, 2020Publication date: July 9, 2020Applicant: CELGENE QUANTICEL RESEARCH, INC.Inventors: Zhe NIE, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Publication number: 20200199122Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.Type: ApplicationFiled: February 14, 2020Publication date: June 25, 2020Applicant: CELGENE QUANTICEL RESEARCH, INC.Inventors: Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Publication number: 20200172485Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.Type: ApplicationFiled: February 5, 2020Publication date: June 4, 2020Applicant: CELGENE QUANTICEL RESEARCH, INC.Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Publication number: 20200163946Abstract: The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease. Particular compounds described herein exhibit selective inhibitory activity against CBP compared with BRD4.Type: ApplicationFiled: January 27, 2020Publication date: May 28, 2020Applicant: CELGENE QUANTICEL RESEARCH, INC.Inventors: Lynnie TRZOSS, Juan Manuel BETANCORT, Toufike KANOUNI, Michael Brennan WALLACE, Amogh BOLOOR
-
Publication number: 20200157077Abstract: The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds, and compositions (including pharmaceutical compositions) that include these compounds. The subject compounds and compositions are useful for inhibition of at least one histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer or neoplastic disease, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, retinoblastoma, or multiple endocrine neoplasia type 1.Type: ApplicationFiled: January 24, 2020Publication date: May 21, 2020Applicant: CELGENE QUANTICEL RESEARCH, INC.Inventors: Young K. Chen, Michael Brennan Wallace
-
Patent number: 10654830Abstract: The present embodiments provide for substituted triazolylpyridine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for modulating the activity of histone demethylase enzymes. Additionally, the subject compounds and compositions are useful for the treatment of cancer or other neoplastic diseases, or maladies associated with abnormal histone demethylase activity. Accordingly, the substituted triazolylpyridine derivative compounds described herein are useful in methods and medicaments for treating cancer.Type: GrantFiled: October 23, 2018Date of Patent: May 19, 2020Assignee: CELGENE QUANTICEL RESEARCH, INC.Inventors: Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Patent number: 10617680Abstract: The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease. Particular compounds described herein exhibit selective inhibitory activity against CBP compared with BRD4.Type: GrantFiled: April 18, 2018Date of Patent: April 14, 2020Assignee: CELGENE QUANTICEL RESEARCH, INC.Inventors: Lynnie Trzoss, Juan Manuel Betancort, Toufike Kanouni, Michael Brennan Wallace, Amogh Boloor
-
Patent number: 10611763Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.Type: GrantFiled: September 20, 2018Date of Patent: April 7, 2020Assignee: Celgene Quanticel Research, Inc.Inventors: Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Patent number: 10597379Abstract: The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds, and compositions (including pharmaceutical compositions) that include these compounds. The subject compounds and compositions are useful for inhibition of at least one histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer or neoplastic disease, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, retinoblastoma, or multiple endocrine neoplasia type 1.Type: GrantFiled: July 19, 2018Date of Patent: March 24, 2020Assignee: Celgene Quanticel Research, Inc.Inventors: Young K. Chen, Michael Brennan Wallace
-
Patent number: 10597365Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.Type: GrantFiled: November 13, 2018Date of Patent: March 24, 2020Assignee: CELGENE QUANTICEL RESEARCH, INC.Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
-
Publication number: 20200027531Abstract: A computing entity accesses instances of medical information corresponding to a population of patients and generates a plurality of medical sentences corresponding to the population by, for each patient of the population, generating one medical sentence corresponding to the patient and a timestamp associated with each instance such that the one medical sentence comprises one or more medical codes in a chronological order. The computing entity generates a vector dictionary comprising a plurality of multi-dimensional vectors based on a vector generation model trained using machine learning and the plurality of medical sentences with each multi-dimensional vector corresponding to a medical code. The computing entity generates a digital representation of a first patient of the population using an anagram model and the vector dictionary, determines a health state of the first patient based on the digital representation, and provides an output indicating the health state of the first patient.Type: ApplicationFiled: November 30, 2018Publication date: January 23, 2020Inventors: Patrick White, Somadev Pasala, Donald Johnson, Sreedhar Potturi, Dhaval Shah, Anthony Degliomini, Michael Brennan
-
Patent number: 10526327Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.Type: GrantFiled: May 4, 2018Date of Patent: January 7, 2020Assignee: Celgene Quanticel Research, Inc.Inventors: Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace